ID: MRFR/HC/2665-HCRR | August, 2017 | Region: Global | 90 pages | Half-Cooked Research Reports
Market Synopsis of Global Vesicoureteral reflux market:
Vesicoureteral Reflux (VUR), is a condition in which urine flows backward, from the bladder into the ureters/kidneys. The normal flow of urine is unidirectional from the kidneys to the bladder via the ureters. The backflow is prevented by a 1-way, flap valve at the vesicoureteral junction called ureterovesicular valve. There are two types of VUR, primary VUR and secondary VUR. Primary VUR is caused due to insufficient length of the ureter as compared to its diameter, which causes reduced capacity of the valvular mechanism to control the urine flow. Primary VUR is caused by congential abnormality. Secondary VUR is caused due to overwhelming of ureters' valvular mechanism due to increased bladder pressures associated with obstruction, which may be anatomical or functional. The pressure may distort the ureterovesicular valve needing surgical measures to correct the deformity. These signs and symptoms can include a strong and persistent urge to urinate which is often associated with a burning sensation when urinating, high frequency of urinating in small amounts, occurrence of blood in the urine often with a strong smell, fever, abdominal pain etc. VUR also cause urinary tract infection (UTI) due to backflow of urine which increases the chances of infection.
The market for VUR diagnosis and treatment is driven by factors such as growing prevalence of urinary tract infection, genetic predisposition and occurrence at birth (congenital), increasing screening etc. It must also be noted that white population and girls are at a higher risk of developing VUR.
The growing awareness and the availability of advanced biocompatible products such as dextranomer and hyaluronic acid gels which are injected to treat VUR are expected to make a positive impact on the market. VUR Injection marks an advancement over the current surgery treatment as it is minimally invasive and requires less hospital stay. Development of surgical robots will drive the future market as they are more precise, cause less trauma. However, the minimally invasive surgeries are more expensive which will act as a drag on the market. Over all the rising per capita income and the growing acceptance of the surgeries across the globe will drive the future market. The critical market restraints are complications and discomfort associated with VUR diagnosis and treatment, invasive nature of the open surgery, infections etc.
Considering all these factors, the market for VUR diagnosis and treatment is expected to reach $ 1.1 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 4.7 % during 2017-2023.
Sources: Mayo Clinic, MRFR Analysis.
Figure 1 Global VUR market by Surgery, 2016 (% Market Share)
The global VUR market is segmented on the basis of types, diagnosis, drug treatment, surgery and end users. Based on types, the market has been segmented as primary VUR and secondary VUR. Based on the diagnosis, the market has been segmented as cystography, voiding cystourethrogram (VCUG), ultrasound, scintigraphy, urinalysis and others. Based on the drug treatment, the market has been segmented as quinolones, aminoglycosides, β-lactam, azoles and others. Based on the surgery, the market has been segmented as open surgery, robotic-assisted laparoscopic surgery, endoscopic surgery and others. Based on the end users, the market has been segmented as hospitals and clinics, academics and research and others.
US accounts for the maximum market share due to favorable insurance penetration, excellent reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global VUR diagnosis and treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Key players of Global Vesicoureteral reflux market:
Key players profiled in the report are Salix Pharmaceuticals, Q-Med Scandinavia Inc., Cook Medical, Salix Pharmaceuticals, Ltd., Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., and others.
The report for Global Vesicoureteral Reflux Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Table of Contents
1.2 scope of study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.3 Market Structure:
2. Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3. Market dynamics
3.4 Macroeconomic Indicators
4. Market factor analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
5. Global Vesicoureteral reflux market, by Types
5.1 Primary Vesicoureteral Reflux
5.2 Secondary Vesicoureteral Reflux
6. Global Vesicoureteral reflux market, By Diagnosis
6.3 Voiding Cystourethrogram (VCUG)
7. Global Vesicoureteral reflux market, by Drug Treatment
8. Global Vesicoureteral reflux market, by Surgery (
8.2 Open Surgery
8.3 Robotic-Assisted Laparoscopic Surgery
8.4 Endoscopic Surgery
9. Global Vesicoureteral reflux market, By End Users
9.1 Hospitals And Clinics
9.2 Academics And Research
10. Global Vesicoureteral reflux market, By Region
10.1 North America
10.4 Middle East & Africa
11. Competitive landscape
11.1 Major Strategies Adopted By Market Players
11.1.1 Strategic Partnership
11.1.2 Merger & Acquisition
12. Company profile
12.1 Salix Pharmaceuticals
12.1.2 Product Overview
12.1.4 Key Developments
12.2 Q-Med Scandinavia Inc.
12.2.2 Product Overview
12.2.4 Key Developments
12.3 Cook Medical
12.3.2 Product Overview
12.3.4 Key Development
12.4 Salix Pharmaceuticals, Ltd.,
12.4.2 Product Overview
12.4.4 Key Developments
12.5 Bayer AG
12.5.2 Product Overview
12.5.4 Key Developments
12.6 Novartis AG
12.6.2 Product Overview
12.6.4 Key Developments
12.7 Pfizer Inc.
12.7.2 Product Overview
12.7.4 Key Developments
12.8 F. Hoffmann-La Roche Ltd
12.8.2 Product Overview
12.8.4 Key Developments
13.1 Key Findings
13.1.1 From Ceo’s Viewpoint
13.1.2 Unmet Needs Of The Market
13.2 Key Companies To Watch
13.3 Prediction Of Vesicoureteral Reflux Diagnosis And Treatment Industry